Cross-Sector entity
ICOTYDE is most often covered alongside Protagonist Therapeutics, which appears in 2 of these 2 stories. The clearest coverage concentration is fda-approval: 1 of 2 stories, with the rest divided among 1 other category. The tracked stories average 2 original sources each.
2 verified stories tracked
Last mentioned: Jun 14, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
ICOTYDE is most often covered alongside Protagonist Therapeutics, which appears in 2 of these 2 stories. The clearest coverage concentration is fda-approval: 1 of 2 stories, with the rest divided among 1 other category. The tracked stories average 2 original sources each. ICOTYDE appears in 2 tracked Cross-Sector stories from June 14, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ICOTYDE. Shared-story counts are live from our verified record — not editorial picks.
Protagonist Therapeutics has transitioned from binary clinical risk to execution risk, with ICOTYDE's FDA approval and rusfertide's Priority Review. Backed by $620 million in cash, the company's validated peptide platform and royalty-based revenue model offer a compelling biotech investment thesis.
Protagonist Therapeutics' shift to a royalty-driven, capital-light model ensures sustained funding for two near-term peptide drug launches. With over $620 million in cash, the company is poised to deliver new treatment options while minimizing financial risk.
Source: Equity Eagle · Equity Eagle
